38 Result(s)

Article

APC/C^Cdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells

Hematopoietic stem and progenitor cells (HSPCs) represent the lifelong source of all blood cells and continuously regenerate the hematopoietic system through differentiation and self-renewal. The process of di...

Daniel Ewerth, Stefanie Kreutmair, Andrea Schmidts… in Cellular and Molecular Life Sciences (2019)

Article

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Multiple myeloma is a disease typical of the elderly, and, because of the increase in life expectancy of the general population, its incidence is expected to grow in the future. Elderly patients represent a pa...

Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, Evangelos Terpos… in Leukemia (2018)

Article

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Combining the kinase inhibitor sorafenib with allogeneic stem cell transplantation boosts immune responses against a subtype of acute myelogenous leukemia, suggesting potential clinical benefit.

Nimitha R Mathew, Francis Baumgartner, Lukas Braun, David O'Sullivan… in Nature Medicine (2018)

Chapter

Ruxolitinib

Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis (MF) by the US F...

Stefanie Ajayi, Heiko Becker, Heike Reinhardt… in Small Molecules in Hematology (2018)

Chapter

Pomalidomide

Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as immunomodulatory. Pomalidomide, the recent immunomodulatory agent (IMiD), has sho...

Monika Engelhardt, Stefanie Ajayi, Heike Reinhardt… in Small Molecules in Hematology (2018)

Chapter

Carfilzomib

Carfilzomib (CFZ) is a potent, second-generation proteasome inhibitor (PI), with significant activity as a single agent and in combination with other antimyeloma agents in patients with relapsed or refractory ...

Monika Engelhardt, Magdalena Szymaniak-Vits… in Small Molecules in Hematology (2018)

Protocol

The Use of SNAP Labeling to Study Cell Cycle Oscillatory Proteins

Tightly controlled degradation of specific regulatory proteins is crucial for transitioning to the next cell cycle phase, ensuring precise DNA replication and an equal distribution of chromosomes to provide ge...

Christine Greil, Marie Follo, Monika Engelhardt, Ralph Wäsch in Cell Cycle Oscillators (2016)

Article

Analysis of survival by tumor response: have we learnt any better?

Gabriele Ihorst, Johannes Waldschmidt, Martin Schumacher… in Annals of Hematology (2015)

Article

ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes

The inhibitors of DNA binding (ID) inhibit basic helix-loop-helix transcription factors and thereby guide cellular differentiation and proliferation. To elucidate the involvement of IDs in hematopoiesis and ac...

Annette M. May, Anna-Verena Frey, Lioudmila Bogatyreva… in Histochemistry and Cell Biology (2014)

Chapter

Ruxolitinib

Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologi...

Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff… in Small Molecules in Oncology (2014)

Chapter

Pomalidomide

Pomalidomide (originally CC-4047 or 3-amino-thalidomide) is a derivative of thalidomide that is antiangiogenic and also acts as an immunomodulator. Pomalidomide, as the newest immunomodulatory agent (IMiD), ha...

Monika Engelhardt, Ralph Wäsch, Heike Reinhardt… in Small Molecules in Oncology (2014)

Article

NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantation

Allogeneic hematopoietic cell transplantation (HCT) is a curative approach for several diseases predominantly affecting elderly patients. Overall survival is compromised by treatment-related mortality (TRM), G...

Peter S. Haas, Gabriele Ihorst, Susanne Schnitzler, Ralph Wäsch… in Annals of Hematology (2012)

Article

Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance

We analyzed the safety and efficacy of rituximab plus bendamustine (R-B) in elderly and frail patients with aggressive B-non-Hodgkin lymphoma (a-B-NHL). Few reports have as yet reported on R-B in a-B-NHL, albe...

Julia Horn, Martina Kleber, Stefanie Hieke, Annette Schmitt-Gräff… in Annals of Hematology (2012)

Article

Stevens–Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation

Ralph Wäsch, Thilo Jakob, Kristin Technau, Jürgen Finke… in Annals of Hematology (2012)

Article

Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells

Genomic instability can be found in most cancer cells. Cell proliferation is under tight control to ensure accurate DNA replication and chromosome segregation. Cyclin-dependent kinases (Cdks) and their activat...

Ralph Wäsch, Dirk Engelbert in Oncogene (2005)

Article

APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit

Cyclin degradation is central to regulation of the cell cycle. Mitotic exit was proposed to require degradation of the S phase cyclin Clb5 by the anaphase-promoting complex^1,2 activated by Cdc20 (APC^Cdc20)³. Furt...

Ralph Wäsch, Frederick R. Cross in Nature (2002)